Gene · 9436
Papers3,322
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 3,322
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting cancer stem cells as the most aggressive and tumor-initiating cells. | Transl Oncol | 2026 | 41604836 | PubTator, text mining | PubMed |
| Multiphysics-Driven Assembly of Biomimetic Vesicles. | Adv Mater | 2026 | 41589794 | PubTator, text mining | PubMed |
| Fifty Years of Natural Killer Cells: Milestones and Future Horizons. | Scand J Immunol | 2026 | 41580304 | PubTator, text mining | PubMed |
| Resident CD49a+CD103+NKG2C+ NK cells restrict HIV infection in human lymphoid tissue explants. | Sci Adv | 2026 | 41576166 | PubTator, text mining | PubMed |
| Multi-platform analysis of the tumor immune microenvironment associated with breast cancer subtypes. | Oncoimmunology | 2026 | 41530924 | PubTator, text mining | PubMed |
| Profiling NK cell receptor repertoire of women with idiopathic recurrent pregnancy loss. | J Reprod Immunol | 2026 | 41313910 | PubTator, text mining | PubMed |
| Immune and Biological Changes during Treatment in Patients with Nonsegmental Vitiligo and their Relation to Repigmentation. | J Invest Dermatol | 2026 | 40848929 | PubTator, text mining | PubMed |
| A ligand-centered framework for γδ T cell activation in colorectal cancer revealed by single-cell and transformer-based perturbation. | Front Immunol | 2025 | 41607803 | PubTator, text mining | PubMed |
| MicroRNA-mediated regulation of natural killer cells development, effector functions, and antitumor responses. | Cancer Cell Int | 2025 | 41331607 | PubTator, text mining | PubMed |
| Quality standards for NK cell immunotherapies. | Front Bioeng Biotechnol | 2025 | 41306902 | PubTator, text mining | PubMed |
| Crosstalk between decidual natural killer cells and extravillous trophoblasts at the maternal-fetal interface: current status and future perspectives. | Front Immunol | 2025 | 41200190 | PubTator, text mining | PubMed |
| Phenotypes, mechanisms, and therapeutic strategies of natural killer cell immunosenescence. | Immun Ageing | 2025 | 41121385 | PubTator, text mining | PubMed |
| Dysregulated NK cell activation and myeloid-lymphoid imbalance underpin COPD progression: insights from high-dimensional immune profiling and smoking-induced immune remodeling. | Front Immunol | 2025 | 41050685 | PubTator, text mining | PubMed |
| HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques. | Nat Commun | 2025 | 41022728 | PubTator, text mining | PubMed |
| IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy. | Oncoimmunology | 2025 | 40996786 | PubTator, text mining | PubMed |
| Spatial and functional diversity of innate lymphoid cells in the human female genital tract may contribute to antiviral responses to HIV. | Nat Immunol | 2025 | 40983704 | PubTator, text mining | PubMed |
| Nanoscale restructuring of the immune synapse with an engager enhances NK cell function. | Proc Natl Acad Sci U S A | 2025 | 40966288 | PubTator, text mining | PubMed |
| Helixor A enhances natural killer cell activity by induction of PAI-1 expression through the p38/MAPK signaling pathway. | Int Immunopharmacol | 2025 | 40945034 | PubTator, text mining | PubMed |
| Inhibiting the DNA damage repair of HNSCC cells in combination with normo-fractionated radiotherapy influences clonogenicity, senescence and expression of NK cell activation markers. | Sci Rep | 2025 | 40883442 | PubTator, text mining | PubMed |
| A novel feeder cell based on 4-1BBL and membrane-bound IL-21/IL-15 induce highly expansion and anti-tumor effect of natural killer cells. | BMC Biotechnol | 2025 | 40866992 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9436/papers?page=3